HMA updates guide on renewal of drug authorisations in light of EU pharmacovigilance law
This article was originally published in SRA
The Heads of Medicines Agencies in the EU has significantly updated its guideline on how applicants and member states should handle renewals of drug marketing authorisations under the mutual recognition and decentralised procedures1. The update pertains to the new requirements introduced by the EU pharmacovigilance legislation (Directive 2010/84/EU)2.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.